Deep brain stimulation
Ask the expert
The report presents a summary of the reimbursement situation for deep brain stimulation. Indications include Parkinson’s disease, dystonia, essential tremor, cluster headache, and epilepsy.
Clinical scenarios include uni- and bi-lateral implantation of electrodes, implantation of DBS system, adjustment/programming of stimulator, removal of stimulator, and replacement of battery of pulse generation.
The only reimbursement within public / statutory health insurance systems is considered.
The report includes essential information about reimbursement, including:
- Brief country-specific overview of reimbursement system
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions on indications or scenarios for the use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
- The Netherlands
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of the deep brain stimulation devices include:
- Medtronic (Activa)
- Abbot Vscular (Infinity, Brio, Libra)
- Boston Scientific (GUIDE DBS, Vercise)
- Neuropace (RNS System)
- Aleva Neurotherapeutics (directSTIM, spiderSTIM)
- Deep Brain Innovations (DBI) (TOPS)
- Beijing Pins Medical Co (PINS brain pacemaker)
- SceneRay Corporation (DBS system)
- Med-Ally (VersaStim IPG Platform)
Table of content is not available at this moment.
In late September 2021, the Danish Health Data Agency (Sundhedsstyrelsen) has published the update of the Health Care Classification System (Sundheds-væsenets Klassifikations System, SKS). The most significant changes include: 31 new diagnosis codes and 14 procedure codes were added. The newly added procedure codes concern mainly pulmonary and airways area and neuromodulation procedures.Read more
In mid-June 2021, the document "Changes and innovations in the 2022 LKF model" (Änderungen und Neuerungen in den LKF-Modellen 2022) was published. The document summarizes the most significant changes and innovations in the LKF model for inpatient and outpatient care. The newly added procedure codes concern mainly the cardiovascular, e-Health, and gastrointestinal area.Read more
For the first time in three years, the Institute for Quality and Efficiency in Health Care (IQWiG) received data within the framework of the early benefit assessment of new examination and treatment methods (NUB) with high-risk medical devices according to §137h of Social Code Book (SGB) V. This involves seven invasive therapeutic cardiovascular, pulmonary, neurological, gastrointestinal, and urological procedures.Read more
In April 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (repetitive short-pulse transscleral cyclophotocoagulation for glaucoma, deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults, and Melphalan chemosaturation for primary or metastatic cancer in the liver) and two Medtech Innovation Briefings (microINR for anticoagulation therapy and RenalSense Clarity RMS for acute kidney injury), and two clinical guidelines (for atrial fibrillation and chronic pain in over 16s).Read more
On April 20, 2021, the Dutch Healthcare Institute (ZIN) published an annual report on the progress of the conditional reimbursement program. In 2020, there were 13 ongoing projects under the program, six of which concerned medical technologies. Furthermore, in 2020, percutaneous transforaminal endoscopic discectomy for the treatment of lumbosacral radicular syndrome in lumbar disc herniation was included in the basic insurance package as regular care.Read more